Beta-Cyclodextrin supported on Fe3O4-Carbon Nanotube Coated with 3,4,5-Trihydroxybenzoic Acid (Fe3O4-CNT@β-CD@THBA) as Nanocarrier for Drug Delivery
نویسندگان
1 Navoi State University, Navoi, Uzbekistan
2 Fergana State Technical University, Fergana, Uzbekistan
3 Tashkent University of Information Technologies named after Muhammad al-Khwarizmi, Tashkent, Uzbekistan
4 Bukhara State Medical Institute, Bukhara, Uzbekistan
5 Bukhara State Medical Institute, Bukhara, Uzbekistan
6 University of Geological Sciences, Mirzo Ulugbek district, Tashkent, Uzbekistan
7 Tashkent State Technical University, Tashkent, Uzbekistan
8 Samarkand State Medical University, Samarkand, Uzbekistan
9 Termez State University, Termez, Uzbekistan
10 Jizzakh Polytechnic Institute, Jizzakh, Uzbekistan
11 Jizzakh State Pedagogical University, Jizzakh, Uzbekistan
12 Urgench State University named after Abu Rayhon Beruniy, Urgench, Uzbekistan
13 Mamun University, Khiva, 220900, Uzbekistan
doi
10.22052/JNS.2025.03.043چکیده
This study introduces a novel nanocarrier system based on Fe₃O₄ supported on carbon nanotubes, functionalized with beta-cyclodextrin (β-CD) and coated with 3,4,5-trihydroxybenzoic acid (THBA), aimed at enhancing targeted drug delivery. The nanocomposite was synthesized through a multi-step process involving co-precipitation, oxidation, and surface modification, and characterized using SEM and XRD analyses, confirming successful fabrication and preservation of the magnetic core structure. The nanocarrier demonstrated high drug loading capacity (15 mg/g) and encapsulation efficiency (78%), with controlled and sustained release behavior evaluated in vitro within various ionic media reflecting physiological conditions. Kinetic modeling revealed Fickian diffusion as the primary release mechanism, with nearly complete drug release over 72 hours. Cytotoxicity assays using MCF-7 breast cancer cells indicated biocompatibility and potential for therapeutic application. The nanocarrier’s magnetic properties enable targeted delivery, while the surface modifications facilitate controlled release, stability, and biocompatibility. These attributes position the Fe₃O₄-CNT@β-CD@THBA nanocarrier as a promising platform for site-specific and sustained drug delivery, demonstrating significant potential in nanomedicine for improved therapeutic outcomes.
